Advertisement
YOU ARE HERE: LAT HomeCollections

Business Briefing / Pharmaceuticals

Bone drug tests well, Amgen says

August 04, 2009|Times Wire Reports

Amgen Inc.'s experimental drug denosumab worked as well as Novartis' Zometa in preventing fractures in patients with advanced cancers whose disease had spread to their bones, the company said.

The 1,776-patient trial found that denosumab reduced the risk of fractures and other bone complications as effectively as Zometa, Amgen said.

Amgen, based in Thousand Oaks, is seeking approval in the U.S. and Europe to sell the drug to treat osteoporosis.

Advertisement
Los Angeles Times Articles
|
|
|